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Abstract
A three-stage continuous fermentative colonic model system was used to monitor in vitro
the effect of different orange juice formulations on prebiotic activity. Three different juices
with and without Bimuno, a GOS mixture containing galactooligosaccharides (B-GOS) were
assessed in terms of their ability to induce a bifidogenic microbiota. The recipe development
was based on incorporating 2.75g B-GOS into a 250 ml serving of juice (65°Brix of concen-
trate juice). Alongside the production of B-GOS juice, a control juice – orange juice without
any additional Bimuno and a positive control juice, containing all the components of Bimuno
(glucose, galactose and lactose) in the same relative proportions with the exception of B-
GOS were developed. Ion Exchange Chromotography analysis was used to test the mainte-
nance of bimuno components after the production process. Data showed that sterilisation
had no significant effect on concentration of B-GOS and simple sugars. The three juice for-
mulations were digested under conditions resembling the gastric and small intestinal envi-
ronments. Main bacterial groups of the faecal microbiota were evaluated throughout the
colonic model study using 16S rRNA-based fluorescence in situ hybridization (FISH). Po-
tential effects of supplementation of the juices on microbial metabolism were studied mea-
suring short chain fatty acids (SCFAs) using gas chromatography. Furthermore, B-GOS
juices showed positive modulations of the microbiota composition and metabolic activity. In
particular, numbers of faecal bifidobacteria and lactobacilli were significantly higher when
B-GOS juice was fermented compared to controls. Furthermore, fermentation of B-GOS
juice resulted in an increase in Roseburia subcluster and concomitantly increased butyrate
production, which is of potential benefit to the host. In conclusion, this study has shown B-
GOS within orange juice can have a beneficial effect on the fecal microbiota.
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Introduction
The concept of modulating gut health through diet is not new and dates back to at least the be-
ginning of the 20th century. More recently, sound scientific rationales have been proposed and
investigated [1].
Dietary substrates reaching the large intestine are able to influence the composition and ac-
tivities of indigenous bacteria through their fermentation capacities [2, 3]. Prebiotics, specifi-
cally inulin-type fructooligosaccharides (FOS) and galactooligosaccharides (GOS) are known
to support the growth of beneficial bacteria, such as bifidobacteria, and numerous intervention
studies have shown such properties in vivo [4, 5].
Since 2006 much research has implicated the gut microbiota and the regulation of host im-
munity in the development of different conditions such as metabolic syndrome and associated
disorders [6,7]. Therefore, through studying the gut microbiota in metabolic disease and the
subsequent impact of prebiotics potential future new therapeutic approaches may be devel-
oped. Galacto-oligosaccharides are prebiotics that have been shown in human feeding studies
to selectively stimulate the growth of bifidobacteria [8–11] and lactobacilli. Moreover, human
studies on infants have shown GOS to offer benefits in terms of stool consistency, while in-
creasing bifidobacterial numbers [12,13] in adults, GOS have also been seen to alleviate symp-
toms of irritable bowel syndrome [8].
Recently, much attention has been focused on the properties of prebiotics to be incorporat-
ed into food products whilst not negatively impacting on organolectic properties and maintain-
ing stablity during food processing. There is a considerable amount of information on the
stability of prebiotics, in particular, GOS, FOS and inulin, mainly from experiments using
model systems and to a lesser extent with real foods. GOS in general are very stable under acid-
ic conditions and high temperatures and for this reason they can be potentially added to a vari-
ety of acid or heated foods, such as yogurts, fermented milks, buttermilk, pasteurised fruit
juices and bakery products [14,15].
The stability of gal-polyols and oligosaccharides during pasteurization at a low pH in vari-
ous fruit juices has also been demonstrated; in most cases, more than 99% of GOS survived pas-
teurization [16]. To date, the reason for the high stability of GOS is the presence of b-linkages,
although other factors, such as the sugar residues present, the ring form and the anomeric con-
figuration can play a role too [16].
Controversially, inulin and FOS have been suggested to be less stable than other oligosac-
charides at conditions of low pH and high temperatures.
Suggested further work in the topic includes the evaluation of the stability of established pre-
biotics in real food systems rather than model solutions, as there is a lack of data on this and the
scarce existing data suggest that the food matrix can influence prebiotic stability. A lack of data
exists also in regard to emerging prebiotics. Another important technological aspect of prebio-
tics is their effect on the physicochemical and organoleptic properties of the food product.
In respect to GOS, there are few commercial examples of GOS-containing food products,
and very little information on the impact of GOS on the physicochemical properties of the
food carrier.
In the current study, three foods were developed, a novel prebiotic-fortified juice, a juice
with matching sugar concentration and a placebo juice. Post-processing, the carbohydrate con-
centrations (simple sugars and added prebiotic) were assessed via ion-exchange chromatogra-
phy. By using initial pre-digestion under similar conditions to the upper gastrointestinal tract
partially digested foods likely to persist to the colon can be investigated. In the present study,
the impact of the three juice products on the human intestinal microbial ecosystem was investi-
gated using an in vitro three-stage continuous culture system which simulated the human large
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intestine (colon model). The colonic model provides a controlled environment to assess micro-
bial changes and organic acid production. The main bacterial groups of the faecal microbiota
were evaluated during the study using 16S rRNA-based fluorescence in situ hybridization
(FISH) approach.
Materials and Methods
Galactooligosaccharide mixture (B-GOS)
A prebiotic GOS mixture (B-GOS; BiMuno) was provided in powder form and supplied by
Clasado Ltd, Milton Keynes, United Kingdom. The product was in dry powder form consisting
of (wt:wt) 48% GOS with a degree of polymerization between 2–5, 22% lactose, 18% glucose
and 12% galactose.
Preparation of orange juices
The orange juices were prepared in batches of 500ml, which is equivalent to two servings of
juice. To produce the juices, an orange juice concentrate was sourced from Minute Maid,
(Coca-Cola, London, UK) and diluted with either water, a BiMuno solution or a solution of
mixed carbohydrates (glucose, galactose, maltodextrin, lactose), to achieve a Brix value of
11.2°C for each orange juice; the Brix value of the juice concentrate was 65°C. In Table 1 the
nutritional composition in 240 ml is reported. The target concentration of BiMuno in the
B-GOS juice was 5.5g per 250ml serving, i.e. 2.75g B-GOS. The composition of the three pro-
duced orange juices is reported in Table 2. The juices were batch pasteurized at 65°C for 30
minutes and then freeze dried.
Analysis of B-GOS
To determine whether the sugar concentrations were maintained after the juice production
processes, the AOAC 2001.02 (method 32–33) based on the methodology described by de
Slegte [17]. The carbohydrate composition of the reaction mixture was determined by high
performance anion exchange chromatography coupled with pulsed amperometric detector
(HPAEC-PAD). A Dionex system (Dionex corporation, Surrey, UK) consisting of a GS50
Table 1. Nutritional composition in 240mL serving size.
Amount Per Serving Calories 110
% Daily Value+,*
Total Fat 0g 0%
Sodium 15mg 1%
Potassium 450mg 13%
Total Carb 27g 9%
Sugars 24g
Protein 2g Not a signiﬁcant source of protein
Vitamin C 130% Calcium 2%
Thiamin 10% Niacin 2%
Vitamin B6 4% Folate 15%
Magnesium 6%
+ Not a signiﬁcant source of calories from fat, saturated fat, trans fat, cholesterol, dietary ﬁber, vitamin A
and iron;
* Percent Daily Values are based on a 2,000 calorie diet.
doi:10.1371/journal.pone.0121955.t001
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gradient pump, an ED50 electrochemical detector with a gold working electrode, an LC25
chromatography oven, and an AS50 autosampler was used. Separation was performed using a
pellicular anion-exchange resin based column, CarboPac PA-1 analytical (4mm×250 mm),
connected to a CarboPac PA1 Guard (4mm×50mm) (Dionex corporation, Surrey, UK). The
column was maintained at 25°C; elution was performed at a flow rate of 1ml/min using gradi-
ent concentrations of sodium hydroxide and sodium acetate solutions. All chromatographic
analyses were performed in triplicate.
Simulated human digestion of juice (from mouth to small intestine)
Frozen juice samples of orange juices were thawed and 60g of each sample were digested by an
in vitro simulation of the upper gut digestion. The remaining solution was dialysed with a
membrane of 100–200 Daltons cut off (Spectra/por 100–200 Da MWCO dialysis membrane,
Spectrum Laboratories Inc., UK) to remove monosaccharides from the digested juices and the
retentate, the product was then freeze dried for use in the in vitro systems as described by Mac-
caferri et al. [18].
Collection and stool sample preparation
Faecal samples were obtained from volunteers at risk of metabolic syndrome (two males, one
female; age 30 to 38 years; BMI: 18.5–25). Faecal samples were collected on site, kept in an an-
aerobic cabinet (10% H2, 10% CO2 and 80% N2) and used within a maximum of 15 minutes
following voiding. Samples were diluted 1/10 w/w in anaerobic PBS (0.1 mol/L phosphate buff-
er solution, pH 7.4) and homogenized (Stomacher 400, Seward, West Sussex, UK) for 2 min-
utes at 240 paddle beats per minute.
Three-stage continuous culture colonic model system
The three-stage continuous culture model of the human colon comprised of 3 glass fermenters
of increasing working volume, simulating the proximal (V1, 280 mL), transverse (V2, 300 mL)
and distal colon (V3, 320 mL). The 3 fermenters, connected in series, were kept at 37°C, pH
was maintained at 5.5 (V1), 6.2 (V2) and 6.8 (V3) and anaerobic conditions were introduced
by continuously sparging with O2-free N2 at a rate of 15 mL/min. The fermentation system was
designed and validated to reproduce the spatial, temporal, nutritional, and physicochemical
characteristics of the microbiota in the human colon [19]. V1 was fed by means of a peristaltic
pump with a culture medium previously described [18] and consisting of the following chemi-
cals (g/L) in distilled water: starch, 5.0; pectin (citrus), 2.0; guar gum, 1.0; mucin (porcine gas-
tric type III), 4.0; xylan (oatspelt), 2.0; arabinogalactan (larch wood), 2.0; inulin, 1.0; casein
(BDH Ltd.), 3.0; peptone water, 5.0; tryptone, 5.0; bile salts No. 3, 0.4; yeast extract, 4.5; FeSO4.
Table 2. Ingredients for orange juice preparation.
Control B-GOS Juice Mixed sugar juice
Water (mL) 417 417 417
Concentrate (mL; 65°Brix) 83 83 83
BiMuno (g) 0 11 0
Glucose (g) 0 0 0.73
Galactose (g) 0 0 0.48
Maltodextrin (g) 0 0 1.21
Lactose (g) 0 0 8.6
doi:10.1371/journal.pone.0121955.t002
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7H2O, 0.005; NaCl, 4.5; KCl, 4.5; KH2PO4, 0.5; MgSO4.7H2O, 1.25; CaCl2.6H2O, 0.15;
NaHCO3, 1.5; cysteine, 0.8; hemin, 0.05; Tween 80, 1.0.
Each stage of the colonic model was inoculated with 100 mL faecal slurry. The total system
transit time was 48 h. Following inoculation, the colonic model was run as a batch culture for
24 h in order to stabilise the bacterial populations prior to the initiation of medium flow. After
24 h (T0), the medium flow was initiated and the system ran for 8 full volume turnovers to
allow for steady state to be achieved (SS1) (assessed through stabilisation of the SCFA profiles
(+/-5%). Taking into account, the operating volume (900 mL) and the retention time (48 h) of
the colonic model system, the dialysis retentate of the different juices was added daily into V1
at 1% (w/v). The tested juices were added to the system for a further 8 volume turnovers upon
which steady state 2 (SS2) was achieved.
In vitro enumeration of bacteria population by FISH
Numbers of the 9 main intestinal bacterial groups, as well as total bacterial populations, were
evaluated by FISH analysis, as previously described by Martin-Pelaez and colleagues [20]. The
probes used are reported in Table 3 [22–27] and were commercially synthesized and 5’-labelled
with the fluorescent Cy3 dye (Sigma-Genosys, UK).
Short chain fatty acids (SCFAs) analysis by gas chromatography
Aliquots of 1 ml collected from each vessel in microcentrifuge tubes were centrifuged at 13000
g for 5 min. The supernatants were transferred into fresh microcentrifuge tubes and stored at
-20°C until use. Samples were derivatized based on the method of Richardson et al., [21]. The
supernatants stored at -20°C were thawed on ice and centrifuged at 13000 g for 10 min. 500 μL
of each supernatant were transferred into fresh microcentrifuge tubes and 25 μL of internal
standard (2-ethyl butyric acid) followed by 250 μL of concentrated HCl and 1 mL of ether
added to each tube. Tubes were vortexed for 1 min and centrifuged at 3000 g for 10 min. The
top ether layer was collected and transferred into fresh microcentrifuge tubes. Aliquots
(400μL) of the ether extract were pipetted into a Wheaton vial and then 50 μL of N-tertButyldi-
methyl silyl N-methyltrifluoroacetamide (MTBSTFA) was added. The vials were sealed tightly
by screwing after addition of MTBSTFA and heated at 80°C for 20 min in a water bath. Sam-
ples were transferred to Agilent crimp cap vials for gas chromatography analysis. Vials were
Table 3. Oligonucleotide probes used in this study for FISH analysis.
Probe Target group Reference
EUB338a Most bacteria [22]
EUB338IIa Most bacteria [22]
EUB338IIIa Most bacteria [22]
Bac303 Bacteroides spp. [23]
Bif164 Biﬁdobacterium spp. [23]
Lab158 Lactobacillus-Enterococcus spp. [24]
Erec482 Most of the Clostridium coccoides-Eubacterium rectale group (Clostridium
cluster XIVa and XIVb)
[25]
Chis150 Clostridium histolyticum group [26]
Prop853 Clostridium cluster IX [27]
Rrec 5842 Roseburia subcluster [28]
Fprau655 Faecalibacterium prausnitzii and related sequences [28]
a, bThese probes are used together in equimolar concentrations
doi:10.1371/journal.pone.0121955.t003
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capped with Crimp top natural rubber/PTFE seal type 7 aluminium silver 11 mm Chromacol
caps and sealed using a crimper. The capped vials were left at room temperature for 48 h for
derivatization. Calibration was achieved using standard solutions of derivitized acetic, propi-
onic, i-butyric, n-butyric, i-valeric, n-valeric, and n-caproic acids as described for the test sam-
ples. The final concentration of each standard was 25, 10, 5, 1, and 0.5 mM. The derivatized
samples were run through a 5890 series II GC system (HP, Crawley, West Sussex, UK) fitted
with SGE-HT5 column (0.32 mm × 25 m × 0.1 μm; J&W Scientific, Folsom, CA, USA) and
flame ionisation detector. Helium was used as the carrier gas and was delivered at a flow rate of
14 mL/min. The head pressure was set at 10 psi with a split ratio of 10:1. Injector, column and
detector were set at 275, 250 and 275°C respectively. One micro liter quantity of each sample
was injected with a run time of 10 min. Peaks were integrated using the Atlas Lab managing
software (Thermo Lab Systems, Mainz, Germany). Organic acid concentrations were quanti-
fied by calculating the relative response factors as compared to the internal standards and cal-
culating concentrations within the samples accordingly.
Statistical analysis
Data were analyzed by one-way ANOVA, using Tukey’s post-test analysis when the overall P
value of the experiment was below the value of significance (P< 0.05). An additional paired t-
test was applied in order to assess the significance of results of single pairs of data. Analyses
were performed using GraphPad Prism 5.0 (GraphPad Software, La Jolla, CA, USA).
Results
Analysis of B-GOS in juices
On average, the quantity of B-GOS recovered in B-GOS-juice was approximately 0.022g per
ml, indicating that that 250ml provides 2.75g of B-GOS. Results therefore show that no loss of
B-GOS was encounterd during the food processing or storage.
Effects of different juices on prebiotic functionality in colonic model
The human intestinal microbiota was assessed before and after supplementation with B-GOS
juice, a control juice which had no added prebiotic, and a positive control juice which con-
tained a mixed sugar concentrate to provide carbohydrates equivalent to the B-GOS juice.
The administration of control juice did not mediate any significant change in the concentra-
tions of the bacterial groups that were investigated (Supplementary material). On the other
hand, the B-GOS juice mediated a significant increase in numbers of bacteria within the Bifi-
dobacterium genus (detected by Bif164) in all the stages of the colonic model system (from
8.15 to 9.10 log CFU/ml in V1 [P = 0.0003], from 7.91 to 9.14 log CFU/ml in V2 [P = 0.003])
and from 8.10 to 9.09 CFU/ml [P = 0.0029] in V3) whereas the lactic acid bacteria group
(LAB) significantly increased in V1 (from 8.24 to 8.81 log CFU/ml in V1 [P = 0.05]. Moreover,
an overall decrease of the Clostridium cluster I and II (detected using Chis 150) was observed
in vessel 1 (from 7.83 to 7.29 log CFU/ml in V1 [P = 0.042]), whereas the Roseburia/E. rectale
groups increased from 8.04 to 9.02 log CFU/ml in V1 [P = 0.0023], from 8.05 to 8.49 log CFU/
ml in V2 [P = 0.002]) (Fig. 1). Similar to B-GOS juice, the mixed sugar juice induced a signifi-
cant increase in bifidobacteria in vessel 1 (from 7.77 to 8.53 log CFU/ml in V1 [P = 0.034].
Furthermore, an overall decrease of the E. rectale/Clostridium cluster XIVa group V1 was ob-
served following supplementation of mixed sugar juice (from 8.98 to 8.34 log CFU/ml in V1
[P = 0.05], as well as a decrease in Roseburia/E. rectale groups (from 8.68 to 7.40 log CFU/ml
in V1 [P = 0.048]) (Fig. 2).
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Short chain fatty acid analysis
Short chain fatty acids (SCFAs), which are the principal end products of gut bacterial metabo-
lism, were measured in the three different vessels of the colonic model systems, at SS1 and SS2
by gas chromatography (Table 4). The administration of B-GOS juice in V1 induced a signifi-
cant increase in butyrate (29.93 to 41.43 mM; P<0.001) and acetate (from 38.79 to 60.94 mM;
P = 0.002) from SS1 to SS2 (Table 4). The administration of mixed sugar juice in V1 induced a
significant decrease in butyrate (49.93 mM in SS2 to 40.14 mM in SS1, P = 0.002) (Table 4).
When mixed sugar juice was added into the colonic system, the acetate levels increased signifi-
cantly in V1, from SS1 to SS2 (Table 4, P = 0.002). None of the changes in the concentrations
of SCFAs in all vessels at SS2 were significant with the control juice when compared to SS1
(Table 4), which is in accordance with the microbiological data.
Fig 1. Bacterial groups detected by FISH in culture broths recovered from vessels (V1, V2 and V3) of an in vitro colonic model before (SS1) and
after (SS2) daily administration of B-GOS juice.Results are reported as mean of the data of three colonic models (Log10 CFU/mL) ± standard deviations
(SD).
doi:10.1371/journal.pone.0121955.g001
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Discussion
A prebiotic juice was developed in the current study and using in vitro assessment the prebiotic
functionality of the final product was maintained, as compared to control products. The juice
development was based on incorporating 2.75g B-GOS into an acceptable serving of orange
juice. The Bimuno product naturally contains about 52% simple sugars, these would normally
be digested in the upper gastrointestinal tract, therefore just the B-GOS would persist to the
large intestine, to create an effective control for this in vitro work a product with match sugar
concentration was developed, furthermore, a placebo juice, without these additional sugars was
also developed. Therefore with optimal pre-digestion the control products would be expected
to perform similarly in the model systems and lead to no changes between steady state 1 and 2.
B-GOS juice induced positive modulations of the microbiota composition and metabolic ac-
tivity. In fact, B-GOS juice mediated significant increases of Bifidobacterium spp. in all three
vessels of the model system. Bifidobacteria is a genera associated with many positive effects in-
cluding immunomodulation and reducing IBS symptoms [23, 8, 9]. As such, this change is re-
garded as a potential benefit. This bifidogenic (prebiotic) effect has been observed on
Fig 2. Bacterial groups detected by FISH in culture broths recovered from vessels (V1, V2 and V3) of an in vitro colonic model before (SS1) and
after (SS2) daily administration of mixed sugar juice. Results are reported as mean of the data of three colonic models (Log10 CFU/mL) ± standard
deviations (SD).
doi:10.1371/journal.pone.0121955.g002
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consuption of B-GOS, whilst not within a matrix [8– 10]. The mixed sugar juice also led to in-
creases in bifidobacteria in the first vessel of the model system, but this change was of a smaller
magnitude to that seen with the B-GOS juice, thus indicating the additional ability of B-GOS to
positively modulate the microbiota within the juice matrix. The bifidogenic effect of the mixed
sugar juice, and not the control juice, indicates that sugars used in juice manufacture were not
completely removed in the pre-digestion process and are therefore available for fermentation;
this is unlikely to be the case in vivo. The control juice did not lead to any significant changes
to the microbiota, thus indicating a lower persistence of the sugars through the initial in vitro
predigestion compared to the other juice preparations. Lactic acid bacterial numbers increased
significantly in vessel 1 of the B-GOS juice supplemented model; this potentially beneficial ef-
fect was not observed following fermentation of the mixed sugar juice, thereby showing an en-
hanced effect of the B-GOS juice. Similarly in human studies B-GOS supplementation has led
to increased levels of lactobacilli [9]. The bifidobacterial and lactobacilli changes show that the
prebiotic functionality of the B-GOS was maintained post product processing.
Further microbial effects observed upon fermentation of the B-GOS juice, but not the
mixed sugar juice, included a decrease in the C. histolyticum group. This group, although pres-
ent in the healthy gastrointestinal tract, contains some known potential pathogens, therefore a
decrease in numbers is seen to be of benefit. Indeed, Vulevic et al., [9] also observed B-GOS to
impact on this microbial group. In addition to this, the mixed sugar juice fermentaion led to an
increase in this microbial group, which is indicative of the non-selective fermentation nature of
the sugars within this particular preparation.
Table 4. Short-chain fatty acids concentrations in culture broths recovered from vessels (V1, V2 and V3) of an in vitro colonic model before (SS1)
and after (SS2) the daily administration of B-GOS containing juice, mixed sugar juice and control juice, as assessed by GC analysis.
Metabolites Vessel 1 (V1) Vessel 2 (V2) Vessel 3 (V3)
Before B-GOS
orange Juice(SS1)
After B-GOS
orange Juice (SS2)
Before B-GOS
orange Juice(SS1)
After B-GOS
orange Juice (SS2)
Before B-GOS
orange Juice(SS1)
After B-GOS
orange Juice (SS2)
Acetate 38.79 ± 5.78 60.94 ± 1.79a 69.23 ± 3.13 79.67 ± 6.20 68.01 ± 2.14 70.70 ± 8.24
Propionate 57.45 ± 1.77 63.09 ± 2.33 55.51 ± 2.55 62.69 ± 5.76a 69.31 ± 4.89 70.71 ± 2.69
Butyrate 29.93 ± 11.53 40.43 ± 3.29a 52.04 ± 6.70 50.12 ± 6.85 62.97 ± 5.29 61.58 ± 2.05
Metabolites Vessel 1 (V1) Vessel 2 (V2) Vessel 3 (V3)
Before Mixed sugar
orange Juice(SS1)
After mixed sugar
orange Juice (SS2)
Before Mixed
sugar orange Juice
(SS1)
After mixed sugar
orange Juice (SS2)
Before Mixed
sugar orange Juice
(SS1)
After mixed sugar
orange Juice (SS2)
Acetate 48.79 ± 5.78 60.92 ± 1.79b 59.10 ± 2.13 79.67 ± 6.20 62.08 ± 1.98 70.70 ± 8.24
Propionate 47.45 ± 1.77 53.05 ± 2.10 51.42 ± 1.87 56.69 ± 4.56a 59.28 ± 3.89 64.71 ± 1.69
Butyrate 49.93 ± 11.53 40.14 ± 2.34 b 54.03 ± 3.70 48.91 ± 5.78 52.97 ± 4.28 59.88 ± 5.05
Metabolites Vessel 1 (V1) Vessel 2 (V2) Vessel 3 (V3)
Before control
orange Juice(SS1)
After control
orange Juice (SS2)
Before control
orange Juice(SS1)
After control
orange Juice (SS2)
Before control
orange Juice(SS1)
After control
orange Juice (SS2)
Acetate 52.79 ± 3.68 59.94 ± 1.79 69.23 ± 3.13 72.67 ± 5.20 78.01 ± 2.14 80.70 ± 8.24
Propionate 44.38 ± 1.77 52.19 ± 1.33 55.51 ± 2.55 62.69 ± 5.76a 69.31 ± 4.89 74.71 ± 2.69
Butyrate 53.43 ± 8.43 47.43 ± 3.29 52.04 ± 6.70 55.12 ± 7.85 62.97 ± 5.29 61.58 ± 2.05
For each sample, measurements were performed in triplicate. Results are means (mM) of the measurements in the two colonic models ± standard
deviation (SD).
aDesignates signiﬁcant differences between SS1 and SS2 at conﬁdence level of P<0.05
bDesignates signiﬁcant differences between SS1 and SS2 at conﬁdence level of P<0.05.
doi:10.1371/journal.pone.0121955.t004
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B-GOS juice also lead to additional increases of the Roseburia subcluster, a change correlat-
ed with a potentially beneficial butyrogenic effect following B-GOS juice administration. Buty-
rate is associated with many benefits in terms of colonic health [4]. For example, it is the
preferred energy source for colonic epithelial cells, and promotes normal cell differentiation
and proliferation. Additionally, both the B-GOS juice and the mixed sugar juice fermentation
generated increases in acetate. The metabolic fate of acetate is within the muscles, kidney, brain
and heart [28] Furthermore, bifidobacteria are acetate producers, but do not form butyrate,
therefore it is possible that butyrate was produced by acetate utilisation, by bacteria in the Rose-
buria group [29]. SCFAs, in addition, help to regulate sodium and water absorption, and can
enhance absorption of calcium and other minerals as well as lower the colonic pH. This latter
modification has the potential to inhibit growth of putative pathogens providing an additional
potential benefit to the host [30, 31, 32]. Within this study the faecal samples were collected
from individuals with metabolic syndrome, to see if this product could be appropriate for mod-
ulating the microbiota in those at risk of developing cardiovascular disease and diabetes. As
this group of individuals has been considered to have a modified microbiota that may benefit
from increased bifidobacteria levels [33]. The results of this in vitro work show positive modu-
lations of the microbiota and indicate that more work with B-GOS juice in those at risk of met-
abolic syndrome would be appropriate to determine if microbial changes can improve other
associate metabolic syndrome parameters, as seen in murine studies [34].
Overall the findings showed that functionaility of B-GOS was maintained within the B-GOS
juice, therefore supporting the utilization of prebiotic enriched juice for potentially improving
gastrointestinal health. Further work is however, required to assess if this functionality is also
maintained in vivo, within a population at risk of metabolic syndrome.
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